Introduction
============

Skin has evolved as a protective barrier against environmental stresses such as physical damage, ultraviolet radiation exposure and pathogenic infections. It is a complex tissue, consisting of many cell types, including keratinocytes, immune cells, melanocytes, fibroblasts, adipocytes, nerve fibres, smooth muscle and endothelial cells ( [@ref-7]). Skin diseases may involve any of these constituent cells, and transcriptomic profiling of diseased human skin can inform understanding of disease pathogenesis. The accessible nature of the skin, unlike tissues such as the brain or liver, and the low patient impact of skin biopsy, make the use of transcriptomics in human skin particularly attractive. Whole punch biopsies have been studied using transcriptome-wide approaches, giving insights into the inflammatory skin disease psoriasis ( [@ref-23]).

Reliably obtaining high quality RNA of sufficient quantity from small samples typical of those derived from punch biopsies is, however, problematic. The reasons for this are diverse and include suboptimal tissue disruption and endogenous RNase activity, resulting in skin being a tissue that is amongst the most challenging to obtain intact RNA from ( [@ref-22])( [@ref-14]). RNA is also a highly unstable molecule. Once extracted from cells or tissues it has a very short half-life and is easily degraded ( [@ref-2]; [@ref-21]). RNA is chemically unstable due to the presence of a hydroxyl group at the 2' and thus is highly susceptible to hydrolysis by ribonuclease enzymes. The hydrolysis or cleavage of RNA can also occur spontaneously, without the presence of a catalyst or enzyme ( [@ref-10]). Together, these challenges may discourage the inclusion of transcriptomics in clinical trials involving human skin, where such information may offer mechanistic insights.

Methods of RNA extraction from human skin have been evolving. Early approaches required large amounts of tissue, and were not amenable to medium/high throughput lysis, as each sample had to be disrupted in liquid nitrogen ( [@ref-12]; [@ref-14]). Whole punch biopsies of the skin have been successfully disrupted by low throughput devices, such as the Kinematica Polytron 1300D homogenizer and FastPrep120 bead beater ( [@ref-1]). 4 mm skin biopsies have also been subjected to ammonium thiocyanate-induced dermo-epidermal separation and subsequently homogenized using bead-based lysis ( [@ref-6]); however the RNA integrity may have been suboptimal due to tissue processing. Importantly none of these approaches allow for histological assessment of the skin sample, which is relevant in interpreting sequencing results of diseased skin. Laser capture microdissection is an alternative method with histological information, with the limitations being cost of laser capture microscopy equipment, small amount of RNA obtained, and RINs that may be lower (circa 7.0) ( [@ref-5]). An additional amplification stage is also often required when starting from small amounts of RNA during library generation, which may introduce an element of bias ( [@ref-13]).

Here we report an efficient method of RNA extraction from skin tumours obtained using punch biopsies under local anaesthetic in a clinical trial involving patients with an inherited skin tumour syndrome. We also validated this method in normal human skin biopsies. Downstream analysis demonstrated high yield and RNA integrity, allowing for transcriptomic profiling using RNA sequencing.

Methods
=======

Ethics
------

Regulatory approvals for the present study were sought and obtained from an ethics review committee (National Research Ethics Service Committee North East-Tyne and Wear Ref:14/NE//080 and 06/1059) and the Medicines Health Regulatory authority (EudraCT: 2014-001342-21). Patients provided written, informed consent for biopsy and use of their tissue samples for research. This study used samples collected as part of a clinical trial, registered at ISCRTN [75715723](https://doi.org/10.1186/ISRCTN75715723). The study was performed in accordance with the Declaration of Helsinki.

Sample collection
-----------------

Tumours scheduled for biopsy as part of the trial protocol were identified using tumour maps and photographs. Tumour identifiers were labelled onto cryovials in advance of the procedure. Skin biopsies were performed under local anaesthetic, and one sample was taken at a time. The biopsy was transferred to a labelled cryovial, with identifiers checked together with a research nurse. The sample was then immediately immersed in liquid nitrogen. All samples were logged in accordance with standard operating procedures and stored in a -80°C freezer within a designated Human Tissue Authority freezer that is subject to temperature monitoring.

Sample processing
-----------------

A full working protocol is detailed in [Supplementary File 1](#SM1){ref-type="other"}, and the key steps are outlined here. Standard precautions to prevent contamination with RNAses were employed. The sample was removed from the freezer and transferred on dry ice to the cryostat. The sample identifier was used to label slides and preweighed lysis tubes, which were supplied prefilled with beads (Precellys). Skin punch biopsy samples of tumours (4--6 mm diameter) were mounted on a cork piece using cutting compound (OCT), and then serially sectioned ( [Figure 1](#f1){ref-type="fig"}). Each skin biopsy was cryosectioned at two levels and ten 30-micron curls were taken from each level for RNA extraction; two were taken from each biopsy. Sections were then taken for histology and applied to a standard slide, and subject to haematoxylin and eosin staining. Following cryosectioning, material was immediately placed into the bead lysis tube, weighed again and then cold lysis buffer (RLT) containing beta-mecaptoethanol was added (Qiagen RNeasy Micro Kit No 74004). The tube was frozen on dry ice and then returned to the -80°C freezer until RNA extraction was performed.

![A method for extracting high quality RNA from small skin biopsy samples which is suitable for RNA sequencing.\
( **a**) Diagram indicating key steps in the work flow, and the need to keep samples cold throughout. (A) Human skin punch biopsy (B) Freezing of sample within 30 seconds. (C--D) Cryostat sectioning of punch biopsy and curls obtained. (E--F) Addition of lysis buffer to single use bead tube, followed by homogenisation in the bead-based lysis machine where up to 24 samples can be processed at once. (G) Silica spin column based RNA extraction performed at 4 degrees. ( **b**) Microfluidic gel analysis of total RNA demonstrates distinct 18S and 28S ribosomal bands, consistent with the high RNA integrity scores ( **c**) demonstrated across samples. ( **d**) FASTQc assessment of reads indicate high quality reads in libraries developed from this dataset.](wellcomeopenres-3-15623-g0000){#f1}

RNA extraction and quality control
----------------------------------

The protocol supplied with the silica spin column kit (Qiagen RNeasy Micro Kit No 74004, Qiagen UK) was followed with modifications, as indicated in the working protocol ( [Supplementary File 1](#SM1){ref-type="other"}). Briefly, bead tubes were taken from the -80°C freezer on dry ice. Tissue was then homogenized in a Precellys Evolution homogeniser (Bertin, France) for 20 seconds at 5500 bpm. After homogenization, the lysate was applied to the column, and then wash steps were performed. On-column DNase digestion was performed for 7 minutes at room temperature. Further washes were performed before RNA was eluted from the column with RNase-free water. All protocol steps were performed in a cold centrifuge at 4°C at 15000 rpm apart from the DNase incubation step stated above. Eluted RNA was measured using the Qubit BR assay kit (Thermofisher, UK). RNA quality was measured using a microfluidic gel electrophoresis chip (Bioanalyer RNA 6000 Nano Chip, Agilent UK). RNA integrity numbers were obtained with the software provided (2100 Expert Software: Revision B.02.09 (SR1)) with the Agilent 2100 Bioanalyser (Agilent, UK) ( [@ref-19]).

Transcriptomic analyses
-----------------------

To obtain the cytokeratin signatures of differentially expressed genes in cylindroma and spiradenoma compared to control skin, three tumour transcript files were compared to three control skin sample files. RNA from each sample was used to generate sequencing libraries using the Illumina Truseq stranded mRNA kit. Libraries were sequenced using an Illumina Hiseq 2500, giving 45 million paired end reads per sample which were 100 bp in length. FASTQ files were checked for quality using FASTQc and aligned using the splice aware aligner program [STAR (v.](https://github.com/alexdobin/STAR/releases) [2.5.2b](https://github.com/alexdobin/STAR/releases/tag/2.5.2b)) to generate alignment files ( [@ref-8]). The read counts for each sample file were obtained using the R package [Subread](https://bioconductor.org/packages/release/bioc/html/Rsubread.html) (v.1.28.1) ( [@ref-15]). Differential gene expression analysis was carried out using [DeSeq2](https://bioconductor.org/packages/release/bioc/html/DESeq2.html) v.1.18.1 ( [@ref-16]). Cytokeratin genes that were differentially expressed with a false discovery rates of \<0.05 after correction for multiple hypothesis testing are listed in [Table 3](#T3){ref-type="table"}.

Results
=======

Consistent high-quality RNA is extracted from multiple skin tumours
-------------------------------------------------------------------

28 skin biopsies were cryosectioned and material with an average weight of 10.4mg (range 5 --14 mg) was obtained at two levels in each biopsy [Figure 1a](#f1){ref-type="fig"}. RNA was obtained from a total of 56 levels, with total yield exceeding the requirements for library preparation for RNA sequencing (yields typically \>500ng) in the majority of samples. Sections taken for histology were stained using haematoxylin and eosin, and confirmed adjacent curls were taken from cylindroma and spiradenoma in 25 out of 28 of biopsies; three biopsies demonstrated trichoepithelioma. In 3 out of 56 levels, RNA was not obtained and this correlated with histology reflecting relatively acellular dermis beneath the level of the tumour. The range of concentrations and quality of RNA extracted from tumours are indicated in [Table 1](#T1){ref-type="table"} and [Figure 1b and c](#f1){ref-type="fig"}, indicating a mean RIN of 9.5 (range 8.5--10). Control skin sample yields and integrity (mean RIN 9.5; range 8.8--10) are indicated in [Table 2](#T2){ref-type="table"}.

###### RNA concentrations and integrity in the 28 skin tumour biopsies studied, with 2 samples taken per biopsy.

Qualitative and quantitative measurements of the total RNA isolated from normal skin punch biopsies.

  Tumour         Samples                Concentration (ng/ul)   RNA integrity
  -------------- ---------------------- ----------------------- ---------------
  1              1                      129.6                   9.7
  2              17.2                   \-                      
  2              3                      63.2                    9.3
  4              too low/undetectable   \-                      
  3              5                      326                     9.3
  6              208                    9.3                     
  4              7                      118                     9.3
  8              76                     9                       
  5              9                      208                     10
  10             142                    9.8                     
  6              11                     115.6                   9.9
  12             29.2                   8.5                     
  7              13                     272                     10
  14             56                     10                      
  8              15                     182.8                   9.6
  16             169.2                  9.6                     
  9              17                     147.4                   9.5
  18             16.6                   \-                      
  10             19                     99.6                    9.4
  20             105.6                  9.3                     
  11             21                     98                      9.5
  22             12.6                   \-                      
  12             23                     41.4                    9.1
  24             82.8                   9.7                     
  13             25                     282                     10
  26             228                    9.9                     
  14             27                     308                     9.9
  28             304                    10                      
  15             29                     258                     10
  30             370                    10                      
  16             31                     800                     10
  32             1120                   10                      
  17             33                     197.8                   9.7
  34             244                    9.6                     
  18             35                     286                     9.6
  36             148                    9.5                     
  19             37                     234                     9.4
  38             250                    9.6                     
  20             39                     362                     9.7
  40             254                    9.6                     
  21             41                     252                     10
  42             55                     10                      
  22             43                     49.6                    9.8
  44             26                     9.5                     
  23             45                     17.2                    9.2
  46             21                     9.8                     
  24             47                     25                      8.6
  48             too low/undetectable   \-                      
  25             49                     360.8                   9.7
  50             194.8                  9.6                     
  26             51                     110.6                   9.3
  52             50.6                   9                       
  27             53                     15.8                    8.7
  54             16.6                   9                       
  28             55                     26.6                    8.8
  56             too low/undetectable   \-                      
  **Average:**   **180.8**              **9.5**                 

###### RNA concentrations and integrity of 10 normal skin samples studied.

Qualitative and quantitative measurements of the total RNA isolated from normal skin punch biopsies.

  -------------------------------------------
  Samples        Concentration\   RNA\
                 (ng/ul)          Integrity
  -------------- ---------------- -----------
  1              25.2             9.6

  2              17               8.8

  3              18.6             9.2

  4              23               10

  5              38.6             9.5

  6              20.2             9.5

  7              32               9.4

  8              36.6             9.4

  9              40               9.8

  10             21.8             9.7

  **Average:**   **27.3**         **9.5**
  -------------------------------------------

###### Expression of known cytokeratin signatures of differentially expressed genes in cylindroma and spiradenoma compared to control skin.

  -----------------------------------------------------------------------------------
  Gene        log2 Fold Change   Prob. FDR     Description
  ----------- ------------------ ------------- --------------------------------------
  *KRT13*     3.94               1.37E-11      Keratin 13

  *KRT17P2*   2.44               0.011702576   Keratin 17 pseudogene 2

  *KRTCAP3*   1.05               0.012251062   Keratinocyte associated protein 3

  *TCHP*      -0.83              0.022666568   Trichoplein keratin filament binding

  *KRT15*     -0.89              0.031124672   Keratin 15

  *KRT3*      -1.56              0.016500418   Keratin 3

  *KRT9*      -1.71              0.002468716   Keratin 9

  *KRT5*      -1.74              0.000610354   Keratin 5

  *KRT8P26*   -1.96              0.012588263   Keratin 8 pseudogene 26

  *KRT80*     -1.96              0.017781638   Keratin 80

  *KRT19*     -2.07              0.035571416   Keratin 19

  *KPRP*      -2.20              0.013678232   Keratinocyte proline rich protein

  *KRTDAP*    -2.35              0.001196344   Keratinocyte differentiation\
                                               associated protein

  *KRT78*     -2.39              0.00676354    Keratin 78

  *KRT10*     -2.46              0.00126146    Keratin 10

  *KRT14*     -2.48              0.00000538    Keratin 14

  *KRT1*      -2.55              0.000588345   Keratin 1

  *KRT77*     -2.67              0.00000744    Keratin 77

  *KRT72*     -2.71              0.000336864   Keratin 72

  *KRT27*     -2.76              0.005439881   Keratin 27

  *KRT73*     -3.37              3.44E-08      Keratin 73

  *KRT31*     -3.89              4.65E-11      Keratin 31

  *KRT2*      -4.02              0.000000475   Keratin 2
  -----------------------------------------------------------------------------------

RNA sequencing validates tumour transcriptomic signature
--------------------------------------------------------

Reads derived from next generation sequencing were subject to quality control using FASTQc ( [Figure 1d](#f1){ref-type="fig"}), and this demonstrated high quality scores, consistent with the high integrity RNA used. Differential gene expression studies focussed on known differentially expressed signature cytokeratin genes in cylindroma and spiradenoma, skin tumours seen in CYLD cutaneous syndrome ( [@ref-3]). This confirmed that the recognised cytokeratin signature was expressed in these tumour transcriptomes ( [Table 3](#T3){ref-type="table"}).

Discussion
==========

Due to its high sensitivity and resolution, RNA sequencing is a powerful tool for investigation of skin disease. It can provide mechanistic insights behind disease pathogenesis, which may offer prognostic information, prediction of response to treatments and the potential for developing novel therapies ( [@ref-11]). To overcome the inherent difficulties of obtaining high integrity RNA, there are in general, four crucial steps required during extraction: cells or tissues should be completely homogenised; nucleoprotein complexes should be disrupted; RNase should be inactivated; contamination including carbohydrate, lipids, protein and other nucleic acid should be avoided ( [@ref-4]; [@ref-9]).

We describe a novel method, incorporating cryostat sectioning, resulting in partial disruption of the tissue, whilst simultaneously allowing us to take 8 μm sections for histological assessment. We used bead-based tubes that allowed for up to 24 samples to be processed simultaneously. Importantly, we were able to work with small amounts of skin, which were robustly disrupted using the bead-based lysis system we employed. This prevented carryover of incompletely homogenised material and obstruction of spin columns used for RNA extraction. The bead-based lysis system we employed had a range of disruption settings and after optimisation with a range of bead sizes, we chose a medium bead mix (CK28 Mix), and lysis of 20 seconds at 5500 rpm in lysis buffer as this gave optimal RNA extraction and RINs.

After skin homogenisation, there are several established methods for RNA extraction. Phenol/chloroform extraction, one of the commonly used techniques, has potential for phenol contamination of the samples, which is often reported ( [@ref-17]). Therefore, we employed a silica column-based RNA extraction methodology ( [@ref-20]). This approach suited our protocol, which required small volumes of lysis buffer, and elution of RNA performed in 14ul of water. This typically resulted in highly concentrated samples and thus satisfied the requirements of most RNA library preparation kits for next generation sequencing.

Given RNA's sensitivity to temperature, we developed a protocol where the skin sample is kept as cold as possible throughout. The tumour samples were first snap frozen in liquid nitrogen, and then cryosectioned at a temperature of -20°C. During rapid homogenisation in our protocol, the tumour material was exposed to ambient temperatures for only a few minutes. This was immediately followed by RNA extraction in a precooled centrifuge at 4°C. Spin columns were incubated on wet ice between centrifugation steps and eluted RNA was immediately frozen after RNA extraction was complete.

In summary, we developed a method for efficient extraction of RNA from small cryosectioned pieces of human skin with histological data from adjacent tissue sections. We validated this method in human skin tumours samples in a clinical trial setting. This protocol could be utilised in healthy and diseased skin to improve mechanistic understanding in a range of human skin disease and cancer.

Data availability
=================

FASTQ files (controls \[n=3\] and tumours \[n=3\] used to generate validation signatures), sample description files and uncropped gel images are available at Open Science Framework: <http://doi.org/10.17605/OSF.IO/5YX96> ( [@ref-18]).

Data are available under the terms of the [Creative Commons Zero \"No rights reserved\" data waiver](http://creativecommons.org/publicdomain/zero/1.0/) (CC0 1.0 Public domain dedication).

Supplementary material {#SM1}
======================

Supplementary File 1: Working protocol.

Click here for additional data file.
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